.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,531,526

« Back to Dashboard

Details for Patent: 7,531,526

Title:Boronic ester and acid compounds, synthesis and uses
Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
Inventor(s): Adams; Julian (Boston, MA), Ma; Yu-Ting (Needham, MA), Stein; Ross L. (Sudbury, MA), Baevsky; Matthew (Grafton, MA), Grenier; Louis (Medford, MA), Plamondon; Louis (Belmont, MA)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Filing Date:Jan 02, 2008
Application Number:12/006,422
Claims:1. A compound having the formula: ##STR00051## or a pharmaceutically acceptable salt thereof; wherein: P is hydrogen or an amino-group-protecting moiety; B.sup.1, at each occurrence, is CH; X.sup.1, at each occurrence, is --C(O)--NH--; X.sup.2 is --C(O)--NH--; R is hydrogen or alkyl, or R forms together with the adjacent R.sup.1, or when A is zero, forms together with the adjacent R.sup.2, a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, and one or two optional substituents selected from the group consisting of keto, hydroxy, aryl, alkoxy and aryloxy; R.sup.1, at each occurrence, and R.sup.2 and R.sup.3 are each independently one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or --CH.sub.2--R.sup.5, where the ring portion of any of said aryl or heterocycle can be optionally substituted; R.sup.5, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or --W--R.sup.6, where W is a chalcogen and R.sup.6 is alkyl, where the ring portion of any of said aryl, aralkyl, alkaryl, or heterocycle can be optionally substituted; provided that at least one of R.sup.1, R.sup.2, or R.sup.3 is ##STR00052## where R.sup.9 is one of alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroarylalkyl; wherein the alkyl is optionally substituted with one of C.sub.1-6alkyl, halogen, monohalo(C.sub.1-6)alkyl, and trifluoromethyl; and wherein said cycloalkyl, aryl, aralkyl, heteroaryl and heteroarylalkyl groups are optionally substituted with one or two of C.sub.1-6alkyl, C.sub.3-8cycloalkyl, C.sub.1-6alkyl(C.sub.3-8)cycloalkyl, C.sub.2-8alkenyl, C.sub.2-8alkynyl, cyano, amino, C.sub.1-6alkylamino, di(C.sub.1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C.sub.1-6)alkoxy, trifluoromethyl, halogen, C.sub.1-6alkoxy, C.sub.6-10aryl, C.sub.6-10aryl(C.sub.1-6)alkyl, C.sub.6-10aryl(C.sub.1-6)alkoxy, hydroxy, C.sub.1-6alkylthio, C.sub.1-6alkylsulfinyl, C.sub.1-6alkylsulfonyl, C.sub.6-10arylthio, C.sub.6-10arylsulfinyl, C.sub.6-10arylsulfonyl, C.sub.6-10aryl, C.sub.1-6alkyl(C.sub.6-10)aryl, and halo(C.sub.6-10)aryl; A.sup.1 and A.sup.2 are independently one of hydrogen, halogen, C.sub.1-6alkyl, monohalo(C.sub.1-6)alkyl, or trifluoromethyl; Z.sup.1 and Z.sup.2 are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z.sup.1 and Z.sup.2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or O; and A is 0, 1, or 2.

2. The compound of claim 1, wherein P is R.sup.7--C(O)--, R.sup.7--SO.sub.2--, R.sup.7--NH--C(O)--, or R.sup.7--O--C(O)--; R.sup.7 is one of alkyl, aryl, aralkyl, heteroaryl, or heteroarylalkyl, any of which can be optionally substituted, or when P is R.sup.7--C(O)--, then R.sup.7 can also be N-morpholinyl.

3. The compound of claim 1, wherein P is R.sup.7--C(O)-- or R.sup.7--SO.sub.2--; and R.sup.7 is one of C.sub.6-10 aryl, C.sub.6-10 ar(C.sub.1-6)alkyl, 5- to 10-membered heteroaryl or 5- to 10-membered heteroaryl(C.sub.1-6)alkyl, any of which can be optionally substituted, or when P is R.sup.7--C(O)--, R.sup.7 can also be N-morpholinyl.

4. The compound of claim 1, wherein one of R.sup.1, R.sup.2, or R.sup.3 is ##STR00053## where A.sup.1 and A.sup.2 are independently one of hydrogen, halogen, C.sub.1-6alkyl, monohalo(C.sub.1-6)alkyl, or trifluoromethyl; R.sup.9 is one of C.sub.1-8 alkyl, C.sub.3-10cycloalkyl, C.sub.6-10aryl, C.sub.6-10ar(C.sub.1-6)alkyl, a 5- to 10-membered heteroaryl, or a 5- to 10-membered heteroaryl(C.sub.1-6)alkyl; and the remaining R.sup.1, R.sup.2, and R.sup.3 are independently selected from the group consisting of alkyl and --CH.sub.2--R.sup.5, where R.sup.5, in each instance, is one of C.sub.6-10aryl, C.sub.6-10ar(C.sub.1-6)alkyl, C.sub.1-6alk(C.sub.6-10)aryl, C.sub.3-10cycloalkyl, C.sub.1-8alkoxy, C.sub.1-8alkoxy, C.sub.1-8alkylthio, or a 5-, 6-, 9-, or 10-membered heteroaryl group, where the ring portion of any of said C.sub.6-10aryl, C.sub.6-10ar(C.sub.1-6)alkyl, C.sub.1-6alk(C.sub.6-10)aryl, C.sub.3-10cycloalkyl, C.sub.1-8alkoxy, C.sub.1-8alkoxy, C.sub.1-8alkylthio, or a 5-, 6-, 9-, or 10-membered heteroaryl can be optionally substituted by one or two substituents independently selected from the group consisting of C.sub.1-6alkyl, C.sub.3-8cycloalkyl, C.sub.1-6alkyl(C.sub.3-8)cycloalkyl, C.sub.2-8alkenyl, C.sub.2-8alkynyl, cyano, amino, C.sub.1-6alkylamino, di(C.sub.1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C.sub.1-6)alkoxy, trifluoromethyl, halogen, C.sub.1-6alkoxy, C.sub.6-10aryl, C.sub.6-10aryl(C.sub.1-6)alkyl, C.sub.6-10aryl(C.sub.1-6)alkoxy, hydroxy, C.sub.1-6alkylthio, C.sub.1-6alkylsulfinyl, C.sub.1-6alkylsulfonyl, C.sub.6-10arylthio, C.sub.6-10arylsulfinyl, C.sub.6-10arylsulfonyl, C.sub.6-10aryl, C.sub.1-6alkyl(C.sub.6-10)aryl, and halo(C.sub.6-10)aryl.

5. The compound of claim 1, wherein A is zero.

6. The compound of claim 1, wherein: A is zero; P is one of R.sup.7--C(O)--, R.sup.7--SO.sub.2--, R.sup.7--NH--C(O)--, or R.sup.7--O--C(O)--; R.sup.7 is one of quinolinyl, quinoxalinyl, pyridyl, pyrazinyl, furanyl, or pyrrolyl, or when P is R.sup.7--C(O)--, R.sup.7 can also be N-morpholinyl; R.sup.2 is: ##STR00054## where A.sup.1 and A.sup.2 are independently one of hydrogen, halogen, C.sub.1-6alkyl, monohalo(C.sub.1-6)alkyl, or trifluoromethyl; R.sup.9 is one of C.sub.1-8 alkyl, phenyl, benzyl, phenethyl, or pyridylmethyl; R.sup.3 is C.sub.1-6alkyl; and Z.sup.1 and Z.sup.2 are independently one of hydroxy, C.sub.1-6alkoxy, or C.sub.6-10aryloxy, or together Z.sup.1 and Z.sup.2 form a moiety derived from a dihydroxy compound selected from the group consisting of pinacol, perfluoropinacol, pinanediol, ethylene glycol, 1,2-cyclohexanediol, 1,3-propanediol, 2,3-butanediol, glycerol, and diethanolamine.

7. The compound of claim 1, wherein said compound is one of: N-(4-morpholine)carbonyl-(O-benzyl)-L-tyrosine-L-leucine boronic acid; or N-(4-morpholine)carbonyl-[O-(2-pyridylmethyl)]-L-tyrosine-L-leucine boronic acid; or a pharmaceutically acceptable salt or boronate ester thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc